Overview

Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Status:
Recruiting

Trial end date:
2023-05-15

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of imetelstat in transfusion dependent participants with low or intermediate-1 risk myelodysplastic syndrome (MDS) that is relapsed/refractory to erythropoiesis-stimulating agent (ESA) treatment.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Geron Corporation
Janssen Research & Development, LLC

Treatments:

Hematinics
Imetelstat
Motesanib diphosphate
Niacinamide